Clinical Trials Logo
  1. Home
  2. Lymphoma, Non-Hodgkin
  3. NCT00398177
  4. Details
NCT00398177 Clinical Trial

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

Lymphoma, Non-Hodgkin Clinical Trial

Official title:
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT00398177
Other study ID # LYM0001
Secondary ID 76973LYM0001IRB-
Status Recruiting
Phase
First received
Last updated
Start date January 1999
Est. completion date January 2099

Study information
Verified date November 2023
Source Stanford University
Contact Ami Okada
Phone 650-725-4968
Email amio@stanford.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.

Description:

This research involves the study of lymphoma cells in order to better understand how the disease grows and spreads. This study may lead to the development of special materials that could be used, in the future, to treat lymphoma or to follow the response of lymphoma to treatment.

Recruitment information / eligibility
Status Recruiting
Enrollment 9999
Est. completion date January 2099
Est. primary completion date January 2099
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification, any stage, any grade. - Adult or pediatric patients receiving lymph node excision for purposes other than cancer therapy (i.e. tonsillectomy, sleep apnea). - A routine procedure for tissue collection is planned. - Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: - Patients without NHL or Hodgkin's disease

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (3)
Lead Sponsor Collaborator
Stanford University Biospect Inc, The Leukemia and Lymphoma Society

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Collection of tumor tissue to characterize the molecular and cell biology of tumor cells in lymphoma. The study will continue indefinitely.
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03484702 - Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma Phase 2
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Completed NCT06190457 - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Completed NCT02369016 - Phase III Copanlisib in Rituximab-refractory iNHL Phase 3
Recruiting NCT01676805 - Tissue Collection for Studies of Lymph Cancer
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Completed NCT00534989 - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT N/A
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00141297 - A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer Phase 1
Completed NCT00322842 - Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients Phase 2
Completed NCT02509039 - A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Phase 1
Completed NCT01573000 - A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) Phase 2
Completed NCT00268203 - Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma Phase 2
Completed NCT03289182 - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)